Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
Nitrase Therapeutics has raised $7.0M in total funding. The most recent round was Series A. The last funding was announced in November 2021.
Nitrase Therapeutics's investors include Sofinnova Partners, Michael J. Fox Foundation, AbbVie, Dementia Discovery Fund, Bristol-Myers Squibb.
Nitrase Therapeutics is headquartered in Jackson, United States.
Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
Nitrase Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nitrase Therapeutics — Funding & Investors." VCBacked, November 2, 2021, https://www.vcbacked.co/company/nitrase-therapeutics. Accessed November 13, 2026.
VCBacked. (2021). Nitrase Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/nitrase-therapeutics
{{cite web |title=Nitrase Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nitrase-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Nitrase Therapeutics? Request a listing update